The simultaneous inhibition of the CXCR4—SDF-1 and PD-1—PD-L1 pathways and the depletion of effector Tregs may enhance the antitumor immune response and reduce mortality in ovarian cancer patients [242,308]. This evidence concerns the gene CXCL12 and ovarian carcinoma.